
The FDA has accepted a Biologic License Application for Vicineum as a treatment option for patients with high-risk, Bacillus Calmette-Guerin-unresponsive non–muscle invasive bladder cancer, and granted it Priority Review,.

The FDA has accepted a Biologic License Application for Vicineum as a treatment option for patients with high-risk, Bacillus Calmette-Guerin-unresponsive non–muscle invasive bladder cancer, and granted it Priority Review,.

The immunotherapy combination of nivolumab and ipilimumab has improved survival and response rates compared with sunitinib, in patients with advanced renal cell carcinoma with sarcomatoid histology, including those with intermediate and poor-risk features.

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each

Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.

Expression or mutations in SAMHD1 does not appear to be linked with failure-free survival or complete remission rates in patients with mantle cell lymphoma who are treated with high-dose cytarabine-based chemotherapy.

In an interview with Targeted Oncology, Nizar M. Tannir, MD talked about how the introduction of nivolumab plus ipilimumab to the front-line setting of sRCC impacts the treatment paradigm.

The team of oncologic professionals at New Jersey’s only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute, has been expanded to include a new chief of gynecologic oncology.

Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.

In the phase 2 FIDES-01 clinical trial, treatment with the FGFR inhibitor, derazantinib, led to an objective response rate of 24% in patients with FGFR2 gene fusion-positive advanced intrahepatic cholangiocarcinoma.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.

After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.

Over the last 10 years, the treatment landscape for biliary tract cancers, specifically intrahepatic cholangiocarcinoma, has evolved and now offers physicians more front- and second-line choices for their patients. For targeted agents in this setting, promising new data have come out for patients with actionable alterations.

The FDA granted Orphan Drug designation to first-in-class LSD1 inhibitor iadademstat, for the treatment of patients with acute myeloid leukemia.

A Biologics License Application was submitted to the FDA for tisotumab vedotin as treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The addition of napabucasin to the FOLFIRI regimen with or without bevacizumab did not demonstrate improvement in overall survival when given as treatment of patients with metastatic colorectal cancer, missing the primary end point of the phase 3 CanStem303C study.

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

The FDA has approved cemiplimab-rwlc, the PD-1 inhibitor, for the treatment of patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog inhibitor is not appropriate.

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

As the population ages and the rate of cancer screenings fall due to the coronavirus disease 2019 pandemic, the lack of rural oncologists underscores the need for advanced practitioners.

The FDA has granted Orphan Drug Designation to the small-molecule tyrosine kinase inhibitor apatinib for the treatment of the rare malignancy, adenoid cystic carcinoma.

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Lee Schwartzberg, MD, medical oncologist, West Cancer Center and Research Institute, discussed the therapeutic options for a 39-year-old woman with HER2-positive breast cancer who was heavily pretreated.

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Delivering the right treatment to the right patient with an eye toward tumor characteristics and gene alterations is at the heart of precision medicine. In this issue, we explore ongoing efforts to achieve precision medicine across disease settings.

The approval of adotrastuzumab emtansine prompted the American Society of Clinical Oncology to issue guidelines regarding the selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer.